Innovating the frontiers of metabolic disease
AGENTIX Corp. (OTC:AGTX), is a clinical-stage biotechnology company that is pursuing the development of a comprehensive suite of novel, science-driven, biopharmaceuticals that target the endocannabinoid system across multiple therapeutic areas with greater market exclusivity, for the treatment of metabolic diseases; including Type 2 Diabetes Mellitus, Chronic Obesity, Non-alcoholic Fatty Liver Disease (NAFLD), and Non-alcoholic Steatohepatitis (NASH). AGENTIX acquired specific assets and licensing rights, including licensing rights associated with intellectual property as part of Worldwide Exclusive Agreements with NHRI (National Heath Research Institute) and RTI (Research Triangle Institute) International.
The Company has identified a targeted collection of Consumer Wellness and Pharmaceutical product opportunities, the majority of which will be designed to offer a more sophisticated and intelligent product offering in the multi-billion-dollar global market. The first category shall consist of a series of products that incorporate a proprietary and proven cellular delivery technology for the Consumer market. Further advancements of these novel biocomplexes will be used in the development and production of pharma-grade products for more specific clinical applications in dermatology, oncology, and neurology. A second proprietary category will include a series of newly created molecules which act specifically on the endocannabinoid receptors for applications regulating metabolism as well as additional indications in nephrology and neurology.
One of the key attributes of these combined companies is the contribution of experienced Management Teams and Scientific Advisors with a collection of industry experience to ensure efficiencies in product development, mitigation of clinical risks, financing and regulatory expertise, and commercialization.
The immediate primary objective is to secure proper financing to advance developments and to support operations. Such positioning will provide opportunities to raise additional working capital, offer liquidity to shareholders, and position the Company for future growth and profitability.